Advertisement
GMED vs VIVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GMED is a Hold and VIVO is a Hold.
GMED's RSI Oscillator recovers from oversold territory
The RSI Oscillator for GMED moved out of oversold territory on September 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 23 similar instances when the indicator left oversold territory. In 16 of the 23 cases the stock moved higher. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on GMED as a result. In 61 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for GMED just turned positive on September 25, 2026. Looking at past instances where GMED's MACD turned positive, the stock continued to rise in 35 of 51 cases over the following month. The odds of a continued upward trend are 69%.
Following a +2.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMED advanced for three days, in 198 of 309 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
GMED broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GMED entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. GMED’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.105) is normal, around the industry mean (10.930). P/E Ratio (19.125) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (1.493) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (3.275) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMED’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Momentum Indicator for VIVO turns negative, indicating new downward trend
VIVO saw its Momentum Indicator move below the 0 level on September 29, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned negative. In 76 of the 81 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VIVO turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 42 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
VIVO moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVO entered a downward trend on October 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVO advanced for three days, in 187 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
VIVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.716) is normal, around the industry mean (17.861). P/E Ratio (35.336) is within average values for comparable stocks, (159.605). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (3.648). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (769.231) is also within normal values, averaging (104.490).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
GMED | VIVO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 58 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 76 Overvalued | 90 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 65 | 100 | |
PRICE GROWTH RATING 1..100 | 49 | 87 | |
P/E GROWTH RATING 1..100 | 54 | 5 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GMED's Valuation (76) in the Medical Specialties industry is in the same range as VIVO (90) in the Biotechnology industry. This means that GMED’s stock grew similarly to VIVO’s over the last 12 months.
GMED's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as VIVO (100) in the Biotechnology industry. This means that GMED’s stock grew similarly to VIVO’s over the last 12 months.
GMED's SMR Rating (65) in the Medical Specialties industry is somewhat better than the same rating for VIVO (100) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than VIVO’s over the last 12 months.
GMED's Price Growth Rating (49) in the Medical Specialties industry is somewhat better than the same rating for VIVO (87) in the Biotechnology industry. This means that GMED’s stock grew somewhat faster than VIVO’s over the last 12 months.
VIVO's P/E Growth Rating (5) in the Biotechnology industry is somewhat better than the same rating for GMED (54) in the Medical Specialties industry. This means that VIVO’s stock grew somewhat faster than GMED’s over the last 12 months.
| GMED | VIVO | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 70% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 69% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 69% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 90% |
| Advances ODDS (%) | 2 days ago 64% | 20 days ago 85% |
| Declines ODDS (%) | 7 days ago 58% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 67% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 60% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GMED’s FA Score shows that 0 FA rating(s) are green while VIVO’s FA Score has 1 green FA rating(s).
- GMED’s FA Score: 0 green, 5 red.
- VIVO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GMED’s TA Score shows that 4 TA indicator(s) are bullish while VIVO’s TA Score has 4 bullish TA indicator(s).
- GMED’s TA Score: 4 bullish, 4 bearish.
- VIVO’s TA Score: 4 bullish, 5 bearish.
Price Growth
GMED (@Medical/Nursing Services) experienced а +3.47% price change this week, while VIVO (@Computer Communications) price change was -32.62% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.79%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -14.87%.
The average weekly price growth across all stocks in the @Computer Communications industry was -7.83%. For the same industry, the average monthly price growth was -10.09%, and the average quarterly price growth was +3.20%.
Reported Earning Dates
GMED is expected to report earnings on Nov 05, 2026.
VIVO is expected to report earnings on Dec 02, 2026.
Industries' Descriptions
@Medical/Nursing Services (-4.79% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Computer Communications (-7.83% weekly)Computer communications industry develops technology that allows computing devices to exchange data with each other using connections/data links between nodes. Common types of computer network include Cloud (IAN), Internet, Wide (WAN, Local (LAN)/Wireless(WLAN) etc. The industry is an ever-more important part of technology, and is set to become even bigger as the Internet of Things (IoT) rapidly forays into the various aspects of our lives. Cisco Systems, Inc., Palo Alto Networks, Inc. and Arista Networks, Inc., Fortinet, Inc. are some of the major computer communications companies.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VPLS | 74.20 | 0.04 | +0.05% |
| Vanguard Core Plus Bond ETF (VPLS) | |||
| SDHY | 15.11 | -0.09 | -0.59% |
| PGIM Short Duration High Yield Opportunities Fund | |||
| DMO | 9.56 | -0.06 | -0.62% |
| Western Asset Mortgage Opportunity Fund | |||
| NVBU | 31.33 | -0.37 | -1.17% |
| AllianzIM U.S. Equity Buffer15 Uncapped Nov ETF (NVBU) | |||
| CATG | 8.67 | -0.56 | -6.07% |
| Leverage Shares 2X Long CAT Daily ETF (CATG) | |||
GMED and
Correlation & Price change
A.I.dvisor indicates that over the last year, GMED has been loosely correlated with TMCI. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then TMCI could also see price increases.
| Ticker / NAME | Correlation To GMED | 1D Price Change % | ||
|---|---|---|---|---|
| GMED | 100% | -0.01% | ||
| TMCI - GMED | 46% Loosely correlated | -1.46% | ||
| TNDM - GMED | 46% Loosely correlated | -3.84% | ||
| SYK - GMED | 44% Loosely correlated | -0.33% | ||
| MDT - GMED | 44% Loosely correlated | +1.31% | ||
| STE - GMED | 43% Loosely correlated | -0.23% | ||
More | ||||